What is the fine-grained topic of the following text: Zalicus Inc. (NASDAQ: ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced the initiation of the SYNERGY trial, a Phase 2b clinical trial evaluating Synavive™, a low-dose glucocorticoid with the potential for amplified immuno-inflammatory benefits, in patients with rheumatoid arthritis (RA). Only return the topic.
Initiation of SYNERGY trial by Zalicus Inc. for Synavive treatment in rheumatoid arthritis patients